GRN, Molecular Health to Expand “Accrual on Demand” for U.S. Cancer Trials

The Guardian Research Network was recognized by the Association of Clinical Research Professionals for their announced collaboration with Molecular Health. The partnership is designed to provide therapeutic clinical trial access and molecular diagnostic decision support to the majority of cancer patients living in U.S. communities.

The organizations will team up to harness the power of “big data” and sophisticated molecular testing to identify cohorts from hundreds of thousands of patients to enable “accrual on demand” for novel cancer trials. This approach aims to ensure site selection efficiency and dramatically reduce the time to complete a clinical trial.

“Working with Molecular Health, GRN physicians will be able to provide their patients with the right drugs, in the right combinations, targeting the drivers of every disease mechanism,” said Molecular Health CEO Lutz Voelker.

Molecular Health has spent more than a decade developing a precision medicine data warehouse and clinical interpretation technologies that relate identified genetic alterations to both approved and experimental drug therapies.

“We are excited to partner with the GRN to rapidly identify molecular subpopulations of patients who might benefit from a specific clinical trial,” Voelker said.

The GRN is forming a nationwide consortium of large, community-based health systems that will utilize Molecular Health’s TreatmentMAP™ 613 gene molecular profile and clinical decision support system as its preferred platform. The network will also use Molecular Health’s InsightMAP™ and OutcomesMAP™ products as underlying technology to support clinical trial matching, patient stratification, and cohort analytics.

“The vast majority of Americans have had little access to sophisticated genomic profiling or to leading-edge clinical trial drugs that offer the best chance for cure, until now,” said Timothy Yeatman, MD, president of the GRN.

Currently, only those cancer patients who are able to travel to tertiary centers can gain access to the majority of novel drug trials.

“We will look back on this innovation in a few years and ask why we hadn’t done it much sooner—it will be a true game changer for pharma, contract research organizations, and others who need a new model to dramatically improve the efficiency and effectiveness of the clinical trials process,” Yeatman said.

Patients, physicians, and hospitals, along with pharmaceutical, diagnostic, and device companies, will benefit from this aligned, innovative effort to democratize clinical trial access and greatly accelerate drug, device, and diagnostic development. The Guardian Research Network continues to invite community health systems with an aligned focus in cancer care to join the rapidly expanding consortium.

The full article can be found here.